Injury, Inflammation and Fibrosis

Organizer(s): Tatiana Kisseleva, Michael Karin and Andrew M. Tager

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. and Theravance Biopharma. This activity was supported by an educational grant from Celgene Corporation.

Summary of Meeting:

Fibrosis is a common response of many organs to chronic injury and inflammation. This leads to destruction of organ architecture with loss of function. Until recently, there have been no therapies to slow the progression of fibrosis and to maintain normal organ function. Recent advances have provided new insights into the pathogenesis of fibrosis, new drug targets, and new drugs in clinical studies. This conference will bring together basic biologists and translational and clinical researchers to discuss core mechanisms underlying inflammation and fibrosis, to compare and contrast fibrotic diseases, preclinical models, the potential for regeneration and regression of fibrosis, and potential therapies. The interaction between the host genetics, the environment and the microbiome in the pathogenesis of fibrotic diseases will be addressed. Also, non-invasive methods to assess fibrosis including advanced imaging and intermediate biomarkers will be discussed. This conference will be a unique opportunity for investigators who are focused on organ-specific diseases – i.e., medical subspecialists – to participate in cross-disciplinary, multi-organ discussions in order to gain new insights into their research.

Scholarship Deadline: November 28 2016

Discounted Abstract Deadline: November 28 2016

Abstract Deadline: January 9 2017

Discounted Registration Deadline: January 23 2017

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Intercept Pharmaceuticals, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 1R13DK112608-01
Funding for this conference was made possible (in part) by DK 112608 -01 from NIH. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations